fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Positive topline results from phase II study evaluating Ampligen (rinatatolimod) for the treatment of post-COVID conditions – AIM ImmunoTech Inc

Written by | 18 Feb 2024

AIM ImmunoTech Inc. announced positive topline results from the Company’s Phase II study evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.